By admin 
The Netherlands-based venture capital firm Forbion has successfully closed two new funds, Forbion Growth Opportunities IV and Forbion Ventures Fund VIII, raising an impressive €2.3 billion, equivalent to approximately $2.6 billion. Announced in a Tuesday statement on October 6, 2026, this landmark fundraise marks the largest in the firm’s history and represents a significant infusion of capital into the European biotechnology industry, which has faced increasing challenges and fallen behind its counterparts in the United States and China. This substantial "dry powder," as described by Forbion, is poised to spur crucial investment in up to 30 promising biotechnology startups, providing a much-needed lift for a sector grappling with a perceived shortage of capital and a shifting global investment landscape.
A Strategic Infusion into European Life Sciences
Forbion’s monumental fundraise arrives at a pivotal moment for the European life sciences sector. The capital, which exceeded the firm’s initial targets for this year, underscores robust investor confidence in Forbion’s strategic vision and its ability to identify and nurture high-potential biotech ventures. With this new capital, Forbion is strategically positioned to address a critical funding gap in Europe, where emerging biotech companies often struggle to secure the substantial investments required to advance groundbreaking research from discovery through clinical development. The firm has already commenced deploying capital from these new funds, with recent notable investments including Sling Therapeutics and Solstice Oncology, signaling an immediate impact on the pipeline of innovative European biotech firms.
Forbion’s Unprecedented Capital Raise
The €2.3 billion secured by Forbion is distributed across two distinct funds, each designed to target different stages of biotech development. Forbion Ventures Fund VIII will likely focus on earlier-stage companies, providing foundational capital for novel scientific discoveries and preclinical development. In contrast, Forbion Growth Opportunities IV is expected to support more mature companies seeking capital for later-stage clinical trials, market access, and commercialization. This dual-fund approach allows Forbion to maintain a comprehensive investment strategy, covering the entire spectrum of biotech company growth. The scale of this fundraise not only solidifies Forbion’s position as Europe’s largest venture fund exclusively dedicated to life sciences but also elevates its global standing as a significant player in biotech investment. The firm now boasts an impressive €7.5 billion in assets under management, reflecting its sustained growth and influence within the global biopharmaceutical ecosystem.
A Beacon Amidst European Biotech’s Challenges
Forbion’s success stands in stark contrast to the broader narrative of a struggling European biotech industry. Over the past few years, a growing chorus of industry leaders, policymakers, and investors has voiced concerns about Europe’s diminishing competitiveness in global pharmaceutical research and development. This fundraise, therefore, is not merely a financial transaction but a powerful statement of belief in the latent potential and scientific excellence within Europe, provided adequate capital and strategic support are available. Sander Slootweg, Forbion’s co-founder and managing partner, articulated this sentiment in the firm’s announcement, stating, "Our successful fundraising gives us significant dry powder in a market characterized by a general shortage of capital." This perspective highlights Forbion’s strategic advantage in a capital-constrained environment, where its substantial resources can be deployed to secure promising opportunities that might otherwise struggle to find funding.
Forbion’s Track Record of Success and Strategic Vision
Forbion’s ability to attract such substantial capital is deeply rooted in its consistent track record of identifying and fostering successful biotech companies. Since its inception, the firm has supported 142 companies, playing a pivotal role in bringing 21 drugs or other medical products to market—a testament to its rigorous selection process and hands-on approach to portfolio management. The firm’s last major fundraise in 2024, which secured $2.2 billion, further demonstrated its capacity to attract significant investment.
A closer look at Forbion’s recent portfolio activity reveals a string of high-profile exits, underscoring the firm’s strategic acumen. Several of its backed companies have been acquired by major pharmaceutical firms, validating their therapeutic platforms and providing substantial returns for investors. These include Capstan Therapeutics, acquired for its innovative in vivo cell therapy capabilities; Mariana Oncology, a specialist in radiopharmaceutical development for cancer; and Aiolos Bio, recognized for its advancements in asthma treatments, particularly TSLP-targeting drugs. Beyond acquisitions, Forbion has also guided companies through successful initial public offerings (IPOs), such as MapLight Therapeutics, which navigated the public markets to secure capital for its schizophrenia drug development.
According to BioPharma Dive data, Forbion has publicly announced at least 55 investments since the start of 2022, cementing its status as one of the biopharmaceutical sector’s most active investors during this period. This aggressive investment pace, coupled with a string of successful exits, demonstrates Forbion’s robust deal flow and its proficiency in navigating complex market dynamics. The firm’s strategic vision extends beyond mere capital provision; it involves active mentorship, strategic guidance, and fostering collaborations that accelerate drug development and market entry.
The Broader Landscape: Europe’s Lagging Biotech Sector
The timing of Forbion’s announcement is particularly salient given the growing concerns about Europe’s position in the global biotech race. For years, analysts and industry observers have pointed to a widening gap between European biotech and its counterparts in the United States and, increasingly, China. This disparity is not merely anecdotal but is supported by various metrics, including venture capital inflows, the number of clinical trials conducted, and the overall share of global pharmaceutical research and development.
Recent reports and industry analyses indicate that while European scientific output remains strong, the translation of this research into commercially viable products and therapies is hampered by a complex interplay of factors. Data from various financial institutions and industry trackers consistently show that venture capital funding for European biotech companies, while growing, still lags significantly behind the U.S. and China. For instance, while specific figures fluctuate year-on-year, the U.S. typically captures a disproportionately large share of global biotech venture dollars, often exceeding 50% of total investment, whereas Europe’s share frequently hovers in the 15-25% range. This capital deficit creates a challenging environment for European startups, making it harder to fund long, expensive development cycles and compete for top talent.
Moreover, the regulatory environment in Europe has been cited as a potential deterrent. While stringent regulatory processes are vital for patient safety, perceived inefficiencies or slower approval pathways compared to other regions can discourage companies from conducting trials or launching products in Europe. This has led to a noticeable shift in clinical trial activity, with a decreasing number of new trials initiated in Europe and a corresponding increase in regions like China, where government support and greater regulatory flexibility can expedite development.
Calls for Policy Reform and Systemic Change
The frustration within the European biotech community reached a crescendo last month when nine prominent board chairs of leading European biotech companies issued an open letter pressing for urgent policy changes. Their collective appeal highlighted the systemic issues undermining Europe’s competitiveness and called for a fundamental re-evaluation of how medicine and innovation are perceived and supported across the continent. These executives argued passionately that Europe has mistakenly treated medicine "as a cost to suppress rather than one of the best investments a government can make." This sentiment reflects a deep-seated belief that current policies prioritize cost containment over the long-term societal and economic benefits of fostering a vibrant life sciences industry.
The letter explicitly pointed to the shifting global landscape, where Europe’s share of global pharmaceutical R&D has dwindled, and its capacity to attract and retain top scientific and entrepreneurial talent has been challenged. Much of this activity, they noted, has gravitated towards China, which has strategically invested heavily in its biotech sector through government subsidies, dedicated science parks, and streamlined regulatory processes. The U.S., with its deep capital markets, robust intellectual property protections, and a culture of risk-taking, continues to be a magnet for biotech innovation and investment. The executives’ stark conclusion—"Europe’s alarm bells are ringing"—underscored the urgency of their plea, emphasizing that without concerted action, Europe risks being left behind in the race for future medical breakthroughs.
Investor Confidence and Strategic Partnerships
Despite these overarching challenges, Forbion’s success in raising such a substantial sum speaks volumes about the firm’s reputation and the confidence institutional investors place in its leadership. The diverse group of institutions pouring new funds into Forbion includes prominent Dutch pension managers MN and PGGM, demonstrating a commitment from long-term institutional capital. The participation of the Kauffman Foundation, a leading philanthropic organization focused on entrepreneurship, and Germany’s KfW Capital, a state-owned promotional bank, further highlights broad-based support and a recognition of the strategic importance of biotech investment. Perhaps most notably, the involvement of Eli Lilly, one of the world’s largest pharmaceutical companies, signals a strategic alignment and a validation of Forbion’s investment thesis from a major industry player. Such partnerships are crucial, as they not only provide capital but also open doors to potential collaborations, licensing agreements, and acquisition opportunities for Forbion’s portfolio companies. This blend of institutional, philanthropic, governmental, and corporate investment underscores the perceived value and potential returns offered by Forbion’s disciplined approach to life sciences venture capital.
Implications for the Future of European Innovation
Forbion’s record fundraise offers a critical lifeline and a powerful statement of intent for the European biotech sector. While one fund cannot single-handedly reverse years of decline or solve systemic policy issues, it provides a much-needed injection of capital that can:
- Fuel Innovation: Enable a new generation of European biotech startups to advance their research and development, bringing novel therapies closer to patients.
- Attract Talent: Create attractive opportunities for scientists, entrepreneurs, and executives, potentially mitigating the "brain drain" to the U.S. or other regions.
- Demonstrate Viability: Serve as a proof point that significant capital can indeed be raised and deployed successfully in Europe, potentially encouraging other venture funds and institutional investors to increase their allocations to the sector.
- Strengthen Ecosystems: Support the growth of regional biotech clusters across Europe, fostering collaboration between academia, industry, and healthcare providers.
- Catalyze Policy Change: By demonstrating private sector commitment, it could add weight to the arguments of those advocating for governmental policy reforms, showing that industry is ready to invest if the environment is conducive.
Looking Ahead: A Catalyst for Growth
The €2.3 billion secured by Forbion is more than just a financial milestone; it is a strategic maneuver that positions the firm as a pivotal force in reshaping the future of European biotech. In a market where capital scarcity is a significant hurdle, Forbion’s "dry powder" offers a competitive edge, allowing it to selectively invest in the most promising ventures and nurture them through critical development stages. This could lead to a wave of new medical innovations originating from Europe, addressing unmet medical needs globally.
However, the long-term impact will also depend on the collective response of European governments and regulatory bodies. Forbion’s investment provides the capital, but sustained growth requires an enabling environment characterized by supportive policies, efficient regulatory pathways, and robust public-private partnerships. The fundraise serves as both an immediate boost and a powerful reminder that while private capital can lead the way, systemic challenges require comprehensive, collaborative solutions. As Europe grapples with its competitive standing in the global life sciences arena, Forbion’s latest achievement provides a glimmer of hope and a potential blueprint for revitalization, signaling that despite the alarm bells, the continent’s innovative spirit in biotech remains strong and capable of attracting world-class investment.
